Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist.
about
Obstructive sleep apnea and cognitive impairment: addressing the blood-brain barrierEicosanoid storm in infection and inflammationRegulation of Ketone Body Metabolism and the Role of PPARαP-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenacEndogenous ligands for nuclear receptors: digging deeper.The Pseudomonas aeruginosa N-acylhomoserine lactone quorum sensing molecules target IQGAP1 and modulate epithelial cell migrationLeukotriene B4 antagonism ameliorates experimental lymphedema.The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity.Molecular Mechanisms Underlying the Link between Nuclear Receptor Function and Cholesterol Gallstone Formation.Comparing efficacy of Montelukast versus doxycycline in treatment of moderate acneBasic aspects of tumor cell fatty acid-regulated signaling and transcription factors.Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptorsLoss of 5-lipoxygenase activity protects mice against paracetamol-induced liver toxicityPeroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolismEicosanoids in metabolic syndrome.Nutrient-dependent phosphorylation channels lipid synthesis to regulate PPARα.Identification and characterization of PPARα ligands in the hippocampus.Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis.Nutrigenomic Functions of PPARs in Obesogenic Environments.PPAR Agonists for the Prevention and Treatment of Lung Cancer.Atherosclerosis: an epigenetic balancing act that goes wrong.Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus.Emerging drugs for chronic obstructive pulmonary disease.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Sensing developing biofilms: the bitter receptor T2R38 on myeloid cells.Nuclear receptors and nonalcoholic fatty liver disease.Peroxisome proliferator-activated receptor α ligands and modulators from dietary compounds: Types, screening methods and functions.PPARs and lipid ligands in inflammation and metabolism.Molecular docking of Glyceroneogenesis pathway intermediates with Peroxisome Proliferator- Activated Receptor-Alpha (PPAR-α).PPAR-alpha in cutaneous inflammation.PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia.Inhibition of 5-lipoxygenase attenuates inflammation and BONE resorption in lipopolysaccharide-induced periodontal disease.PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.
P2860
Q26849304-F7FA8839-5618-400C-A4EC-CA38635E1107Q26851985-913856E2-91EE-4D38-9E3F-9F8CA3BDF0C7Q28073224-4175B063-B225-49BB-8A9A-E3C2F66FF3A8Q28539683-0E0D4B64-D2E9-435D-A4F2-4C268926E5C6Q34412495-0FC62FCF-9486-461E-BCA2-212BC2BD0566Q34446638-FBC19784-AF76-42A5-83A0-E4DD7D143B2CQ34556483-6D4C8D94-FD40-491A-B490-3733E19F044DQ35066362-00C47B4A-17D8-4ABC-B1CE-924D467EBD58Q35147692-A6C924C8-E78D-4558-8807-FD6D67A727EEQ35505515-93BD76E4-2168-4912-AE23-F072C3CE6515Q35745309-6CB79D5A-82C9-4493-B9E1-64D8DE66492EQ36294936-9705188C-EAD8-47A1-8AB0-382EE742607BQ36675315-2FF7F5E2-C2D3-4CA3-A48A-317AAD0D8DCEQ36733873-EA8FBAFD-2C38-4974-BC81-58A3DD23785AQ36744182-638E35D1-3DA7-43D9-B5B5-D9F0BA8FE5ACQ36781253-7D0D13AC-8925-4CEA-8D7B-3614F36AFB9DQ36911098-90DDEC5D-670E-41BA-9B7F-3134345CC2A1Q36920576-2EC3C483-B8EF-4D00-BE88-08E85908A58FQ37415763-5590E60B-4BA2-48AE-85F6-E7629B402BD1Q37421898-0A4EB002-7F4E-4D31-A658-087554BC9EC2Q37500797-0DA69B91-F052-4112-98F4-C7ACBD641BFCQ37681630-CC0CE8F2-7070-47AF-90C5-B06BDD07647CQ37850735-92BBBAD4-EC0F-4B76-80AE-85AF48D74483Q37978926-F719C479-F191-4C4C-8138-49ABEF81C5B2Q37984088-E930149A-7FCD-402C-BD42-8ADDA9802F31Q37995534-1E5187EC-D5E8-4FAF-9B00-23E99E711D25Q38346943-8851313A-2F72-4C86-BA87-D971D94DBE64Q38768048-01EBD58A-659B-4E74-A3A7-7C0E938B7ECDQ39013200-B66CF0C8-F3B9-4441-8431-6CC75640BEE9Q41763780-EEF0D6EA-4597-44D3-829F-D317A7C2356CQ41993601-D27EFAB8-98F7-4060-8D07-220F73937DDEQ42665834-871F5242-98C1-4D8A-B042-A6CDDAF484CEQ48247479-D7067E28-E000-4492-AAC9-60CA59E44C79Q49581674-5CBEAB30-09CA-470C-B0F1-5930DAAB4445Q49953684-9008ED56-76B9-444C-AB17-9BC7DDFB809F
P2860
Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@ast
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@en
type
label
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@ast
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@en
prefLabel
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@ast
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@en
P2093
P2860
P356
P1476
Leukotriene B4 is a physiologi ...... ivated receptor-alpha agonist.
@en
P2093
Madathilparambil V Suresh
Raju C Reddy
Ravi K Adapala
Thomas G Brock
P2860
P304
22067-22074
P356
10.1074/JBC.M109.085118
P407
P577
2010-04-16T00:00:00Z